RNA Vaccines

<div>Introduction to RNA Vaccines Post COVID-19.-&nbsp;Self-Replicating RNA Derived from the Genomes of Positive Strand RNA Viruses.-&nbsp;Negative Strand RNA Virus Vectored Vaccines.-&nbsp;New Generation Self-Replicating RNA Vaccines Derived from Pestivirus Genome.-&nbsp;Trans-Amplifying RNA Vaccines Against Infectious Diseases: A Comparison with Non-Replicating and Self-Amplifying RNA.-&nbsp;Generation and Characterization of In Vitro Transcribed mRNA.-&nbsp;Production and Evaluation of Nucleoside-Modified mRNA Vaccines for Infectious Diseases.-&nbsp;Sequence-Optimized mRNA Vaccines Against Infectious Disease.-&nbsp;Design and Synthesis of Circular RNA Expression Vectors.-&nbsp;Electroporation of mRNA as a Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins.-&nbsp;A Basic Method for Formulating mRNA-Lipid Nanoparticle Vaccines in the Lab.-&nbsp;Messenger RNA Lipid-Based Nanoparticles: Optimization of Formulations in the Lab.-&nbsp;Plant Expression of Trans-Encapsidated Chimeric Viral Vaccines with Animal RNA Replicons: An Update.-&nbsp;Producing Plasmid DNA Template for Clinical Grade RNA Vaccine Manufacture.-&nbsp;Regulatory Considerations for Producing mRNA Vaccines for Clinical Trials.-&nbsp;Quality by Digital Design for Developing Platform RNA Vaccine Manufacturing Processes.-&nbsp;Nonclinical Safety Testing of RNA Vaccines.</div>